Targeted therapy outcomes in acrodermatitis continua of Hallopeau: A systematic review
2024

Targeted therapy outcomes in acrodermatitis continua of Hallopeau

Sample size: 134 publication Evidence: moderate

Author Information

Author(s): Zhou ChaoJing, Hou YiYun, Wang YuFei, Lu JiLiang, Gao YaMei, Yin ZhiQiang

Primary Institution: Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University

Conclusion

Targeted therapies are effective for managing refractory acrodermatitis continua of Hallopeau, especially when traditional treatments fail.

Supporting Evidence

  • IL-12/23 inhibitors showed a complete resolution rate of 52.6% within 22.4 weeks.
  • TNF-α inhibitors had a complete resolution rate of 44.1% within 14.6 weeks.
  • IL-17 inhibitors achieved a complete resolution rate of 26.1% within 24.0 weeks.
  • Treatment responses were generally more evident in female patients than in male patients.
  • Many patients faced risks of disability due to the condition.

Takeaway

This study looked at how well different treatments work for a rare skin condition called acrodermatitis continua of Hallopeau, finding that some new medicines help a lot.

Methodology

The study reviewed published data from MEDLINE and Embase, analyzing treatment outcomes from 66 records involving 134 patients.

Potential Biases

There may be reporting bias due to unreported treatment failures.

Limitations

The study lacks evidence from randomized controlled trials and strict monotherapies, and treatment failures are often not reported.

Participant Demographics

Mean age of participants was 44.0 years, with 45.5% being male.

Digital Object Identifier (DOI)

10.7555/JBR.38.20240090

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication